



## ASX ANNOUNCEMENT

### ResApp Signs MOU to Develop Respiratory App for Consumers

**Brisbane, Australia, 18 June 2020** – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, today announced that it has signed a memorandum of understanding with RB, the global health products manufacturer, to develop a smartphone app for consumers that utilises ResApp's cough-based algorithms to identify different respiratory conditions and provide recommended next steps.

ResApp and RB have agreed to exclusively work together to build and test a prototype app for consumers to self-assess, or assess with the assistance of a pharmacist, their respiratory symptoms. This exclusivity may be terminated by either party if a joint development agreement is not signed within six months.

###

#### About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp's machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp's regulatory-approved and clinically-validated products include ResAppDx-EU, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, an at-home sleep apnoea screening app for consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit [www.resapphealth.com.au](http://www.resapphealth.com.au).

#### Contacts for ResApp Health

Dr Tony Keating  
CEO and Managing Director  
+61 430 180 659  
[tony@resapphealth.com.au](mailto:tony@resapphealth.com.au)

Mr Brian Leedman  
Vice President, Corporate Affairs  
+61 412 281 780  
[brian@resapphealth.com.au](mailto:brian@resapphealth.com.au)

*This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.*